Sign In
Buy MYL
$15.86
+0 (+0%)
At Close: May 27, 2022
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYL, IDEX and BKD
10:35pm, Monday, 29'th Jun 2020
NEW YORK, NY / ACCESSWIRE / June 29, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to particip
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
New York, New York--(Newsfile Corp. - June 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of My
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Mylan N.V. – MYL
01:31pm, Monday, 29'th Jun 2020
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and Ma
Pfizer: It's A Whole New Ballgame
08:01am, Monday, 29'th Jun 2020
Pfizer is in the midst of three deals that will transform the company into one that is focused on R&D for prescription medicines. Pfizer is yielding over 4.7% b
Stocks To Watch: Fireworks For Nikola, Tesla And Micron
09:00am, Saturday, 27'th Jun 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX
06:04pm, Friday, 26'th Jun 2020
On June 26, 2020, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0485 per share to shareholders of
The Promise and Perils of Owning Pfizer
07:48pm, Tuesday, 23'rd Jun 2020
The drugmaker offers a dividend yield of almost 4.5% Continue reading...
India gives Hetero Labs approval to make Gilead's COVID-19 drug
11:26am, Sunday, 21'st Jun 2020
India's drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science's experimental COVID-19 treatment remdesivir, the Indian pharmaceutical com
Alzheimer's Drug Approval More Critical for Biogen After Patent Decision
10:04pm, Friday, 19'th Jun 2020
Piper analyst considers OK a longshot and another reason not to be bullish on stock Continue reading...
Upjohn Finance B.V. -- Moody's assigns Baa3 unsecured rating to Upjohn/Viatris' Euro notes offering; outlook stable
08:48pm, Friday, 19'th Jun 2020
Moody's Investors Service ("Moody's") assigned Baa3 senior unsecured ratings to the notes offering of Upjohn Finance B.V. ("Upjohn"). Upjohn is the mature branded business of Pfizer, Inc. ("Pfizer")
Mylan Is Eager to Launch Rival Version of Biogen’s Biggest-Selling Drug After Court Win
03:00pm, Friday, 19'th Jun 2020
Mylan is pressing regulators to approve its generic version of Tecfidera, after defeating Biogen’s patent suit on Thursday.
Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent
02:22pm, Friday, 19'th Jun 2020
Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.
